Spectrum Pharmaceuticals, Inc. (SPPI) Completes Enrollment In Phase 2 Trial Of SPI-2012 - A Novel Long-Acting Granulocyte Colony Stimulating Factor (GCSF) To Treat Chemotherapy-induced Neutropenia
5/28/2014 9:01:32 AM
HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations and with a primary focus in Hematology and Oncology, today announced that the key phase 2 trial of its long-acting granulocyte stimulating factor analog developed using LAPSCOVERY technology (SPI-2012) has completed its Phase 2 study enrollment; this positions Spectrum for Phase 3 decision making before year end.
Help employers find you! Check out all the jobs and post your resume.
comments powered by